title: Difficulties in the management of an incomplete form of refractory thrombotic thrombocytopenic purpura, the usefulness of vincristine.
abstract: BACKGROUND
  Although several etiologies can be identified in thrombotic thrombocytopenic purpura (TTP), idiopathic cases are still frequent. Incomplete forms are more rare. Currently, the diagnosis may be made in cases of thrombocytopenia and microangiopathic hemolytic anemia. According to the literature, mortality and morbidity are significantly improved with plasma exchange. However, treatment in refractory forms remains problematic.
  
  
  METHODS
  A 33-year old woman presented with an incomplete form of TTP, refractory to a combination of therapeutics. The patient underwent plasma infusion, plasma exchange, and then was started on corticosteroids. She also received intravenous immunoglobulins and antiplatelet agents in close proximity to vincristine (Oncovin) infusion. The main biological indicators used were the platelet count, hematocrit, LDH, and the presence of schistocytes. Following vincristine treatment, the patient's condition rapidly improved.
  
  
  CONCLUSIONS
  Vincristine administered after the failure of standard therapeutics was effective in this refractory form of TTP.
authors.affiliation: Epidemiology and Public Health Department - Rouen University Hospital Charles Nicolle, Rouen, France. pierre.chamouni@chu-rouen.fr
authors.forename: P
authors.initials: P
authors.lastname: Chamouni
authors.forename: P
authors.initials: P
authors.lastname: Lenain
authors.forename: G
authors.initials: G
authors.lastname: Buchonnet
authors.forename: V
authors.initials: V
authors.lastname: Merle
authors.forename: C
authors.initials: C
authors.lastname: Bourgain
authors.forename: A
authors.initials: A
authors.lastname: Boyer
authors.forename: C
authors.initials: C
authors.lastname: Girault
authors.forename: P
authors.initials: P
authors.lastname: Czernichow
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D016824:Antigens, Human Platelet / Q000276:immunology; D000963:Antimetabolites / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D001327:Autoimmune Diseases / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D003131:Combined Modality Therapy; D004351:Drug Resistance; D005260:Female; D006400:Hematocrit; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D010949:Plasma; D010951:Plasma Exchange; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011697:Purpura, Thrombotic Thrombocytopenic / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D014750:Vincristine / Q000627:therapeutic use*
chemical_list: D000305:Adrenal Cortex Hormones; D016824:Antigens, Human Platelet; D000963:Antimetabolites; D001323:Autoantibodies; D016756:Immunoglobulins, Intravenous; D010975:Platelet Aggregation Inhibitors; D014750:Vincristine; D001241:Aspirin